Orna Therapeutics
About Orna Therapeutics
Orna Therapeutics is a biotechnology company engineering a new class of fully engineered circular RNA (oRNA) therapeutics to expand RNA medicine beyond traditional approaches. The company focuses on in vivo delivery using its LNP platform to reach sites throughout the body, with initial emphasis on oncology, autoimmune diseases, and infectious diseases, and is based in Watertown, Massachusetts. Orna aims to deliver first-in-class RNA drugs that can treat diseases without harsh preconditioning, leveraging its panCAR in vivo CAR technology and bone marrow targeting. The organization combines scientists, engineers, and seasoned leadership to bring oRNA therapeutics to patients globally.
Recent News
Sickle Cell Disease After Casgevy: Seven Companies to Watch in 2026
Lilly Gets Back in Infectious Disease, via Three M&A Deals
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
Lilly Lands Vaccine Trifecta with 3 New Biotech Buys Valued at up to $3.8B
Goldman Sachs Sets New Biogen Stock Price Target on Bold Alzheimer's Bet
Lilly Strikes Again, Buying CAR-T Firm Orna for $2.4bn
Lilly Adds Gene Delivery Technology to CAR T in up to $7B Kelonia Deal
The Innovators Working to Make in Vivo Cell Therapy a Reality
Lilly Acquiring Kelonia In Largest Funded Biotech Startup Purchase In Years
Lilly Snaps up Engage to Advance Non-Viral Genetic Medicines